Infliximab for Graft Versus Host Disease
Wed, 11 May 2022 09:23:17 -0400
Italiano
Wed, 11 May 2022 09:23:17 -0400
Tue, 10 May 2022 13:12:26 -0400
For the treatment of patients with transfusional iron overload due to sickle cell disease (SCD) or other anemias.
Tue, 10 May 2022 13:01:45 -0400
For the treatment of adults and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
The FDA is warning people not to use the Skippack Medical Lab SARS-CoV-2 Antigen Rapid Tests. The test’s performance has not been adequately established.
SML Distribution Recalls Unauthorized COVID-19 Direct Antigen Rapid Tests because they are not authorized, cleared, or approved by the FDA.
Mon, 09 May 2022 13:54:44 -0400
For the treatment of adult patients with diabetic macular edema (DME) who are pseudophakic and have had an inadequate response to prior anti-vascular endothelial growth factors (VEGF) therapy.
Mon, 09 May 2022 13:42:30 -0400
Cablivi (caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.
Mon, 09 May 2022 10:34:59 -0400
Mesa BioTech’s Accula SARS-CoV-2 Tests are being recalled because facility contamination may cause them to give false positive results.
In recent years, the concept of deprescribing has been introduced, based on the reduction of the number of drugs taken in order to optimize the risk-benefit ratio of polypharmacy taking into account the goals of treatment and the preferences of the patient; however, the available intervention strategies are not numerous.1
80.211.154.110